Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amgen's osteoporosis and bone-related cancer drug denosumab may be one of the most eagerly-anticipated approvals of the year - not least by Amgen itself, whose future growth depends almost entirely on an FDA nod. But in another sense this antibody marks an ending, not a beginning

You may also be interested in...



Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis

New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.

Xarelto Action Letter No Surprise; But Does FDA Want Data, REMS Or Both?

As anticipated, FDA answered Johnson & Johnson/Bayer's NDA for anticoagulant Xarelto (rivaroxaban) with a complete response letter May 28

Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win

Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.

Related Content

Topics

UsernamePublicRestriction

Register

PS004157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel